SMS PharmaceuticalsQ1 FY24

SMS Pharmaceuticals Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹486.5P/E: 39.0Market Cap: ₹4.6K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

No

Order

N/A

Capex

No

0 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3
  • SMS Pharmaceuticals reported a strong Q1 FY24 with 110% year-on-year revenue growth, reaching INR 135 crores.
  • The company expects 15%-20% revenue and profit growth for FY24 compared to FY23.
  • Growth is driven by a robust API business, especially high-volume products like Ibuprofen, with capacity expandable from 700 MT to 1,200 MT/month once 80-85% utilization is achieved.
  • The ARV segment is recovering with expected sustainable volumes in next few quarters.
  • Diversification into anti-diabetic, anti-migraine, anti-ulcer, and anti-ED segments supports stability and growth.
  • Focus on expanding regulated export markets where profitability is higher.
  • Long-term plan includes making Ibuprofen one of the largest globally.
  • Vertical integration for selected high-volume products is underway to improve margins.
  • No major capex planned currently; consolidation and backward integration are priorities.
  • New product launches and geographical expansion efforts are ongoing, with impact expected near fiscal year-end.

See what SMS Pharmaceuticals management said on margin guidance — free account, 30 seconds.

Fundraise plans

No
  • There are no immediate major capex plans or greenfield projects planned at this time.
  • The company intends to consolidate and focus on backward integration of critical, high-volume products.
  • No mention was made of any new fundraising through either debt or equity in the recent call.
  • Current capacity utilization is around 50%-55%, and expansions or major investments will be considered only after optimizing existing capacity.
  • Management did not indicate any plans for raising funds via debt or equity during the discussed period.

See what SMS Pharmaceuticals management said on order book — free account, 30 seconds.

Capex plans

No
  • No immediate major capex or greenfield projects planned at present.
  • Focus is on consolidating current operations and pursuing backward integration for critical, high-volume APIs.
  • Plans for vertical integration are already underway for top five to six key products.
  • Expansion of capacity, such as for Ibuprofen from current 700 metric tons to 1,200 metric tons per month, will only occur after reaching about 80-85% utilization of existing capacity.
  • The company aims to improve operational efficiency and margins through R&D focused on cost and process improvements as well as backward integration.
  • Any major capex expansions are deferred until current capacities are optimally utilized.
  • The approach is cautious with emphasis on sustainable growth and maximizing in-house manufacturing capabilities rather than immediate large-scale investment.

Track SMS Pharmaceuticals — get its next earnings analysis in your feed

How does SMS Pharmaceuticals rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisSMS Pharmaceuticals
Rev 3Mar 3

How does SMS Pharmaceuticals rank in Pharmaceuticals & Biotechnology?

Compare SMS Pharmaceuticals against every Pharmaceuticals & Biotechnology company (Q1 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →